Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), HUTCHMED (HCM – Research Report) and Plus Therapeutics (PSTV – Research Report).

Halozyme (HALO)

Goldman Sachs analyst Corinne Jenkins maintained a Hold rating on Halozyme today. The company’s shares closed last Tuesday at $39.68.

According to TipRanks.com, Jenkins is a 1-star analyst with an average return of -6.9% and a 43.9% success rate. Jenkins covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Springworks Therapeutics.

Currently, the analyst consensus on Halozyme is a Moderate Buy with an average price target of $51.50.

See Insiders’ Hot Stocks on TipRanks >>

HUTCHMED (HCM)

Goldman Sachs analyst Paul Choi maintained a Hold rating on HUTCHMED today and set a price target of $17.00. The company’s shares closed last Tuesday at $19.36.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 10.3% and a 52.2% success rate. Choi covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Vir Biotechnology, and BridgeBio Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HUTCHMED with a $19.55 average price target.

Plus Therapeutics (PSTV)

JonesTrading analyst Justin Walsh maintained a Buy rating on Plus Therapeutics today and set a price target of $32.00. The company’s shares closed last Tuesday at $1.80, close to its 52-week low of $0.97.

According to TipRanks.com, Walsh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -26.5% and a 28.0% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, POINT Biopharma Global, and Fusion Pharmaceuticals.

Plus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.67, representing a 715.0% upside. In a report issued on November 21, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HALO:

• Halozyme’s Vyvgart SC receives European Commission approval
• Halozyme price target lowered to $46 from $48 at Piper Sandler
• HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
• Halozyme raises FY23 adjusted EPS view to $2.70-$2.80 from $2.65-$2.75
• Halozyme reports Q3 adjusted EPS 75c, consensus 73c